{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:19:57Z","timestamp":1772263197523,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca"],"award-info":[{"award-number":["Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10072-025-08188-6","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T02:00:49Z","timestamp":1746583249000},"page":"3797-3802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term safety evaluation of natalizumab during pregnancy and lactation in patients with multiple sclerosis"],"prefix":"10.1007","volume":"46","author":[{"given":"Giannicola","family":"Carrozzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5167-6364","authenticated-orcid":false,"given":"Federica","family":"Pinardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"8188_CR1","doi-asserted-by":"publisher","first-page":"103995","DOI":"10.1016\/j.msard.2022.103995","volume":"65","author":"SA Morrow","year":"2022","unstructured":"Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M, Vosoughi R (2022) Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord 65:103995. https:\/\/doi.org\/10.1016\/j.msard.2022.103995","journal-title":"Mult Scler Relat Disord"},{"key":"8188_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","volume":"88","author":"N Schwab","year":"2017","unstructured":"Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H (2017) Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 88:1197\u20131205. https:\/\/doi.org\/10.1212\/WNL.0000000000003739","journal-title":"Neurology"},{"key":"8188_CR3","unstructured":"Tysabri| European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tysabri#product-info. Accessed 26 May 2024"},{"key":"8188_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12883-016-0674-4","volume":"16","author":"S Friend","year":"2016","unstructured":"Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M (2016) Evaluation of pregnancy outcomes from the Tysabri\u00ae (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol 16:150. https:\/\/doi.org\/10.1186\/s12883-016-0674-4","journal-title":"BMC Neurol"},{"key":"8188_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1212\/CON.0000000000001108","volume":"28","author":"RM Bove","year":"2022","unstructured":"Bove RM, Houtchens MK (2022) Pregnancy management in multiple sclerosis and other demyelinating diseases. Contin Minneap Minn 28:12\u201333. https:\/\/doi.org\/10.1212\/CON.0000000000001108","journal-title":"Contin Minneap Minn"},{"key":"8188_CR6","doi-asserted-by":"publisher","first-page":"e2989","DOI":"10.1212\/WNL.0000000000012084","volume":"96","author":"WZ Yeh","year":"2021","unstructured":"Yeh WZ, Widyastuti PA, Van der Walt A, Stankovich J, Havrdova E, Horakova D, Vodehnalova K, Ozakbas S, Eichau S, Duquette P, Kalincik T, Patti F, Boz C, Terzi M, Yamout BI, Lechner-Scott J, Sola P, Skibina OG, Barnett M, Onofrj M, S\u00e1 MJ, McCombe PA, Grammond P, Ampapa R, Grand\u2019Maison F, Bergamaschi R, Spitaleri DLA, Van Pesch V, Cartechini E, Hodgkinson S, Soysal A, Saiz A, Gresle M, Uher T, Maimone D, Turkoglu R, Hupperts RM, Amato MP, Granella F, Oreja-Guevara C, Altintas A, Macdonell RA, Castillo-Trivino T, Butzkueven H, Alroughani R, Jokubaitis VG, MSBase Study Group (2021) Natalizumab, Fingolimod and dimethyl fumarate use and Pregnancy-Related relapse and disability in women with multiple sclerosis. Neurology 96:e2989\u2013e3002. https:\/\/doi.org\/10.1212\/WNL.0000000000012084","journal-title":"Neurology"},{"key":"8188_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/13524585211023365","volume":"28","author":"E Portaccio","year":"2022","unstructured":"Portaccio E, Tudisco L, Past\u00f2 L, Razzolini L, Fonderico M, Bellinvia A, Ghezzi A, Annovazzi P, Zaffaroni M, Moiola L, Martinelli V, Chisari CG, Patti F, Mancardi G, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Cocco E, Marrosu MG, Comi G, Filippi M, Trojano M, Amato MP, MS Study Group of the Italian Neurological Society (2022) Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Mult Scler Houndmills Basingstoke Engl 28:472\u2013479. https:\/\/doi.org\/10.1177\/13524585211023365","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"8188_CR8","doi-asserted-by":"publisher","first-page":"e723","DOI":"10.1212\/NXI.0000000000000723","volume":"7","author":"AI Ciplea","year":"2020","unstructured":"Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M, Gold R, Hellwig K (2020) Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis Optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation 7:e723. https:\/\/doi.org\/10.1212\/NXI.0000000000000723","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"8188_CR9","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.1212\/NXI.0000000000000769","volume":"7","author":"SC LaHue","year":"2020","unstructured":"LaHue SC, Anderson A, Krysko KM, Rutatangwa A, Dorsey MJ, Hale T, Mahadevan U, Rogers EE, Rosenstein MG, Bove R (2020) Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases. Neurol Neuroimmunol Neuroinflammation 7:e769. https:\/\/doi.org\/10.1212\/NXI.0000000000000769","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"8188_CR10","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ph16111566","volume":"16","author":"L Sportiello","year":"2023","unstructured":"Sportiello L, Di Napoli R, Balzano N, Mascolo A, Ruggiero R, Di Costanzo L, Monaco D, Maniscalco GT, Capuano A (2023) Disease-Modifying therapies (DMTs) in pregnant and lactating women with multiple sclerosis: analysis of Real-World data from eudravigilance database. Pharm Basel Switz 16:1566. https:\/\/doi.org\/10.3390\/ph16111566","journal-title":"Pharm Basel Switz"},{"key":"8188_CR11","doi-asserted-by":"publisher","first-page":"715195","DOI":"10.3389\/fimmu.2021.715195","volume":"12","author":"U Proschmann","year":"2021","unstructured":"Proschmann U, Haase R, Inojosa H, Akg\u00fcn K, Ziemssen T (2021) Drug and neurofilament levels in serum and breastmilk of women with multiple sclerosis exposed to natalizumab during pregnancy and lactation. Front Immunol 12:715195. https:\/\/doi.org\/10.3389\/fimmu.2021.715195","journal-title":"Front Immunol"},{"key":"8188_CR12","doi-asserted-by":"publisher","first-page":"175628642211500","DOI":"10.1177\/17562864221150040","volume":"16","author":"I Callegari","year":"2023","unstructured":"Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T, Lindberg R, Fischer-Barnicol B, Khalil M, Kappos L, Kuhle J, Sanderson NSR, Derfuss T (2023) Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis. Ther Adv Neurol Disord 16:17562864221150040. https:\/\/doi.org\/10.1177\/17562864221150040","journal-title":"Ther Adv Neurol Disord"},{"key":"8188_CR13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"8188_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MPG.0b013e3181da213e","volume":"51","author":"E Bertino","year":"2010","unstructured":"Bertino E, Spada E, Occhi L, Coscia A, Giuliani F, Gagliardi L, Gilli G, Bona G, Fabris C, De Curtis M, Milani S (2010) Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr 51:353\u2013361. https:\/\/doi.org\/10.1097\/MPG.0b013e3181da213e","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"8188_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/0890334414566237","volume":"31","author":"TE Baker","year":"2015","unstructured":"Baker TE, Cooper SD, Kessler L, Hale TW (2015) Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact Off J Int Lact Consult Assoc 31:233\u2013236. https:\/\/doi.org\/10.1177\/0890334414566237","journal-title":"J Hum Lact Off J Int Lact Consult Assoc"},{"key":"8188_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","volume":"11","author":"U Mahadevan","year":"2013","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT (2013) Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 11:286\u2013292 quiz e24. https:\/\/doi.org\/10.1016\/j.cgh.2012.11.011","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"8188_CR17","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.4049\/jimmunol.0903296","volume":"1950 184","author":"T Suzuki","year":"2010","unstructured":"Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol Baltim Md 1950 184:1968\u20131976. https:\/\/doi.org\/10.4049\/jimmunol.0903296","journal-title":"J Immunol Baltim Md"},{"key":"8188_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00919271","volume":"13","author":"H Sarvas","year":"1993","unstructured":"Sarvas H, Sepp\u00e4l\u00e4 I, Kurikka S, Siegberg R, M\u00e4kel\u00e4 O (1993) Half-life of the maternal IgG1 allotype in infants. J Clin Immunol 13:145\u2013151. https:\/\/doi.org\/10.1007\/BF00919271","journal-title":"J Clin Immunol"},{"key":"8188_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/ph16050770","volume":"16","author":"P Gklinos","year":"2023","unstructured":"Gklinos P, Dobson R (2023) Monoclonal antibodies in pregnancy and breastfeeding in patients with multiple sclerosis: A review and an updated clinical guide. Pharm Basel Switz 16:770. https:\/\/doi.org\/10.3390\/ph16050770","journal-title":"Pharm Basel Switz"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08188-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08188-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08188-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:29:02Z","timestamp":1752643742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08188-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["8188"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08188-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agreed with this final version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Alessandra Lugaresi (A.L.) has served as an Amgen\/Horizon, Biogen, Bristol Myers Squibb\/Celgene, Merck Serono, Novartis, Roche, Sanofi\/Genzyme Advisory Board Member. She received congress and travel\/accommodation expense compensations or speaker honoraria from Alexion, Biogen, Merck Serono, Novartis, Roche, Sanofi\/Genzyme, and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis and Sanofi\/Genzyme. Giannicola Carrozzo (G.C.) reports no competing interests. Federica Pinardi (F.P.) reports no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}